A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model

A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model

Anti-PD-1/PD-L1 immunotherapy has limited efficacy in hepatocellular carcinoma (HCC) and does not benefit all patients. A FAK inhibitor (VS-4718) has been reported to improve the microenvironment in some tumors. This study aimed to investigate the effect of the combination of the FAK inhibitor VS471...

Full description

Bibliographic Details
Main Authors: Yuhua Wei, Yufeng Wang, Nanbin Liu, Ran Qi, Yan Xu, Kun Li, Yu Feng, Baomin Shi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Pharmacology
Subjects:
hepatocellular carcinoma
FAK inhibitor (VS4718)
PD1
PD-L1
combination
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.820446/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.820446/full

Similar Items